Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

ConclusionThese real-world data support monthly erenumab 70 or 140  mg s.c. as a safe and effective preventive treatment to reduce headache frequency and severity in chronic migraine patients experiencing previous unsuccessful preventive treatments.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research